Literature DB >> 3479938

Long-term corticosteroid treatment of myasthenia gravis.

T R Johns1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3479938     DOI: 10.1111/j.1749-6632.1987.tb51325.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  13 in total

1.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

Review 2.  Anaesthesia and myasthenia gravis.

Authors:  A Baraka
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

3.  Mortality and survival in myasthenia gravis: a Danish population based study.

Authors:  P B Christensen; T S Jensen; I Tsiropoulos; T Sørensen; M Kjaer; E Højer-Pedersen; M J Rasmussen; E Lehfeldt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

4.  Minimal manifestation status and prednisone withdrawal in the MGTX trial.

Authors:  Ikjae Lee; Hui-Chien Kuo; Inmaculada B Aban; Gary R Cutter; Tarrant McPherson; Henry J Kaminski; Jon Sussman; Philipp Ströbel; Joel Oger; Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Marcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Jan J G Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Greg Minisman; Joshua R Sonett; Gil I Wolfe
Journal:  Neurology       Date:  2020-07-01       Impact factor: 9.910

Review 5.  A practical guide to the recognition and management of myasthenia gravis.

Authors:  A Evoli; A P Batocchi; P Tonali
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 6.  Update on myasthenia gravis.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

7.  A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

Review 8.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

9.  Myasthenia gravis and steroid-induced myopathy of the respiratory muscles.

Authors:  B Vallet; F Fourrier; J F Hurtevent; M Parent; C Chopin
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

10.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.